Abbott Laboratories Comprehensive Income 2010-2024 | ABT
Abbott Laboratories comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Abbott Laboratories comprehensive income for the quarter ending September 30, 2024 was $-7.804B, a 7.97% decline year-over-year.
- Abbott Laboratories comprehensive income for 2023 was $-7.839B, a 2.63% decline from 2022.
- Abbott Laboratories comprehensive income for 2022 was $-8.051B, a 3.86% decline from 2021.
- Abbott Laboratories comprehensive income for 2021 was $-8.374B, a 6.39% decline from 2020.
| Abbott Laboratories Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2023 | $-7,839 |
| 2022 | $-8,051 |
| 2021 | $-8,374 |
| 2020 | $-8,946 |
| 2019 | $-8,465 |
| 2018 | $-7,586 |
| 2017 | $-6,062 |
| 2016 | $-7,263 |
| 2015 | $-6,658 |
| 2014 | $-5,053 |
| 2013 | $-2,012 |
| 2012 | $-3,594 |
| 2011 | $-2,597 |
| 2010 | $-1,367 |
| 2009 | $854 |
| Abbott Laboratories Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-09-30 | $-7,804 |
| 2024-06-30 | $-8,135 |
| 2024-03-31 | $-8,166 |
| 2023-12-31 | $-7,839 |
| 2023-09-30 | $-8,480 |
| 2023-06-30 | $-8,071 |
| 2023-03-31 | $-8,039 |
| 2022-12-31 | $-8,051 |
| 2022-09-30 | $-9,445 |
| 2022-06-30 | $-8,706 |
| 2022-03-31 | $-8,474 |
| 2021-12-31 | $-8,374 |
| 2021-09-30 | $-9,240 |
| 2021-06-30 | $-9,066 |
| 2021-03-31 | $-9,285 |
| 2020-12-31 | $-8,946 |
| 2020-09-30 | $-9,044 |
| 2020-06-30 | $-9,080 |
| 2020-03-31 | $-9,386 |
| 2019-12-31 | $-8,465 |
| 2019-09-30 | $-7,763 |
| 2019-06-30 | $-7,365 |
| 2019-03-31 | $-7,470 |
| 2018-12-31 | $-7,586 |
| 2018-09-30 | $-7,009 |
| 2018-06-30 | $-6,913 |
| 2018-03-31 | $-5,733 |
| 2017-12-31 | $-6,062 |
| 2017-09-30 | $-6,116 |
| 2017-06-30 | $-6,250 |
| 2017-03-31 | $-6,532 |
| 2016-12-31 | $-7,263 |
| 2016-09-30 | $-6,533 |
| 2016-06-30 | $-7,223 |
| 2016-03-31 | $-6,851 |
| 2015-12-31 | $-6,658 |
| 2015-09-30 | $-7,211 |
| 2015-06-30 | $-5,004 |
| 2015-03-31 | $-5,607 |
| 2014-12-31 | $-5,053 |
| 2014-09-30 | $-2,975 |
| 2014-06-30 | $-1,952 |
| 2014-03-31 | $-1,934 |
| 2013-12-31 | $-2,012 |
| 2013-09-30 | $-2,957 |
| 2013-06-30 | $-3,226 |
| 2013-03-31 | $-2,895 |
| 2012-12-31 | $-3,594 |
| 2012-09-30 | $-2,756 |
| 2012-06-30 | $-3,544 |
| 2012-03-31 | $-1,941 |
| 2011-12-31 | $-2,597 |
| 2011-09-30 | $-860 |
| 2011-06-30 | $578 |
| 2011-03-31 | $182 |
| 2010-12-31 | $-1,367 |
| 2010-09-30 | $-1,483 |
| 2010-06-30 | $-2,629 |
| 2010-03-31 | $-976 |
| 2009-12-31 | $854 |
| 2009-09-30 | $499 |
| 2009-06-30 | $-7 |
| 2009-03-31 | $-1,195 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $204.249B | $40.109B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stryker (SYK) | United States | $146.711B | 33.06 |
| Boston Scientific (BSX) | United States | $132.644B | 38.14 |
| EssilorLuxottica (ESLOY) | France | $112.106B | 0.00 |
| Medtronic (MDT) | Ireland | $110.562B | 16.42 |
| Haleon (HLN) | United Kingdom | $43.682B | 28.38 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.166B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $37.665B | 19.54 |
| ResMed (RMD) | United States | $35.786B | 29.41 |
| Terumo (TRUMY) | Japan | $29.739B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.805B | 18.99 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.942B | 13.97 |
| Insulet (PODD) | United States | $18.443B | 73.44 |
| Baxter (BAX) | United States | $16.957B | 11.03 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.065B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.158B | 40.72 |
| Bio-Rad Laboratories (BIO) | United States | $9.320B | 31.68 |
| Demant (WILYY) | Denmark | $8.342B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.294B | 14.62 |
| TG Therapeutics (TGTX) | United States | $5.459B | 0.00 |
| Haemonetics (HAE) | United States | $4.297B | 20.97 |
| Prestige Consumer Healthcare (PBH) | United States | $4.192B | 20.85 |
| ICU Medical (ICUI) | United States | $4.125B | 39.27 |
| Perrigo (PRGO) | Ireland | $3.830B | 11.27 |
| Envista Holdings (NVST) | United States | $3.697B | 27.54 |
| Neogen (NEOG) | United States | $3.246B | 37.45 |
| Agios Pharmaceuticals (AGIO) | United States | $3.175B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.841B | 18.22 |
| QuidelOrtho (QDEL) | United States | $2.700B | 17.38 |
| LeMaitre Vascular (LMAT) | United States | $2.428B | 59.00 |
| Warby Parker (WRBY) | United States | $2.349B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.913B | 33.48 |
| AtriCure (ATRC) | United States | $1.742B | 0.00 |
| InMode (INMD) | Israel | $1.597B | 9.61 |
| AdaptHealth (AHCO) | United States | $1.326B | 9.48 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.318B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $1.267B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.207B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.962B | 16.96 |
| Owens & Minor (OMI) | United States | $0.952B | 7.44 |
| CeriBell (CBLL) | United States | $0.943B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.918B | 30.68 |
| Capricor Therapeutics (CAPR) | United States | $0.847B | 0.00 |
| Evolus (EOLS) | United States | $0.798B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.684B | 30.25 |
| Omeros (OMER) | United States | $0.632B | 0.00 |
| Surmodics (SRDX) | United States | $0.563B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.533B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.522B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.468B | 0.00 |
| Quanterix (QTRX) | United States | $0.451B | 0.00 |
| ZimVie (ZIMV) | United States | $0.391B | 32.95 |
| Valneva SE (VALN) | France | $0.360B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.341B | 32.41 |
| Cerus (CERS) | United States | $0.332B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.330B | 0.00 |
| Biote (BTMD) | United States | $0.325B | 7.12 |
| OraSure Technologies (OSUR) | United States | $0.289B | 19.40 |
| Zynex (ZYXI) | United States | $0.263B | 55.07 |
| Aurora Cannabis (ACB) | Canada | $0.238B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.225B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.221B | 15.29 |
| High Tide (HITI) | Canada | $0.213B | 88.33 |
| MacroGenics (MGNX) | United States | $0.203B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Brainsway (BWAY) | Israel | $0.167B | 100.00 |
| Organigram Holdings (OGI) | Canada | $0.166B | 0.00 |
| Jin Medical (ZJYL) | China | $0.164B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.160B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 18.67 |
| TriSalus Life Sciences (TLSI) | United States | $0.138B | 0.00 |
| Fonar (FONR) | United States | $0.104B | 11.74 |
| Quipt Home Medical (QIPT) | United States | $0.104B | 0.00 |
| Veru (VERU) | United States | $0.099B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.094B | 23.40 |
| Ayr Wellness (AYRWF) | United States | $0.077B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.073B | 37.50 |
| Exagen (XGN) | United States | $0.072B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.065B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| InterCure (INCR) | Israel | $0.062B | 0.00 |
| Modular Medical (MODD) | United States | $0.058B | 0.00 |
| MariMed (MRMD) | United States | $0.057B | 0.00 |
| Apyx Medical (APYX) | United States | $0.054B | 0.00 |
| Safety Shot (SHOT) | United States | $0.051B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| ImmuCell (ICCC) | United States | $0.033B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.028B | 0.00 |
| Flora Growth (FLGC) | United States | $0.019B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.018B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.016B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.009B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Senestech (SNES) | United States | $0.002B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.83 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |